ERBB2 and breast intraductal proliferative lesion: Their results showed that this short-term lapatinib treatment decreased cell proliferation in ductal intraepithelial neoplasia (DIN), ductal hyperplasia without atypia (DH), and invasive erbB-2/Her2+ breast cancer.